HOXC6 (Homeobox C6)

This study identified HOXC6 as a key oncogenic driver in HNSCC and as a candidate biomarker for HNSCC. Targeting HOXC6 could pave the way for improved biomarker-driven approaches in HNSCC treatment to reduce recurrence and improve patient survival rates.

Conclusion While DKK1, HOXC6, and YKT6 did not demonstrate significant differential expression, the study highlights strong associations between OSCC and lifestyle-related risk factors. As the first gene expression study on OSCC in Central India, it underscores the need for larger, tissue-based studies to validate these findings and explore molecular targets for early diagnosis and immunotherapy.

Its high NPV avoids unnecessary biopsies and their associated morbidity. While integrating SelectMDx with mpMRI provides new diagnostic insights, the molecular test revealed superior accuracy when used alone, confirming its importance in precision medicine.

High expression negatively correlated with immune infiltration and decreased StromalScore, ImmuneScore, and ESTIMATEScore. HOXC6 was elevated in other squamous carcinomas.ConclusionHigh HOXC6 expression may promote LUSC and pan-squamous carcinoma development through mitosis regulation.

Stability Volatility Index analysis showed right-sided tumors maintain significantly higher systemic vulnerability. These findings establish anatomical location as a fundamental network organizational principle, suggesting that incorporating temporal dynamics into cancer analysis reveals therapeutically relevant differences for precision medicine applications in colorectal cancer.

AIF1L may regulate MSI CRC progression by promoting ferroptosis, serving as a prospective biomarker for prognosis and a therapeutic target for personalized therapy. This study uncovers new mechanisms in MSI CRC and provides a foundation for optimizing immunotherapy, though further investigation into its specific roles is needed.

Conclusions Based on bioinformatical approaches, we identified significantly enriched gene sets and novel candidates for prognostic markers or therapeutic targets in HNSCC. Further investigation would aid in determining the anti-cancer effects of these candidates.

Our findings provide new insights into the TNBC microenvironment, emphasizing the complex spatial interactions between different cell types and highlighting key regulatory pathways that could be targeted for future therapeutic interventions. This spatial cell atlas lays the foundation for further exploration of tumor microenvironment dynamics and precision oncology approaches.

The test demonstrated a sensitivity of 57.14%, a specificity of 81.82%, a positive predictive value of 40% and a negative predictive value of 90%, with an overall diagnostic accuracy of 77.5%. While age emerged as the only independent predictor in multivariate analysis, SelectMDx showed a strong potential to exclude malignancy and support more selective biopsy strategies.

HOXC6 knockdown inhibits BCAT1 expression to suppress oral cancer development.

In addition, HOXC6 also regulates pathways related to chemical carcinogenesis and reactive oxygen species, with a strong association with the target gene TIMELESS, supported by binding signals in its promoter region. Here, we discuss the role of HOXC6 as a potential biomarker and therapeutic target, contributing to a deeper understanding of the HOXC6-TIMELESS axis and its implications for advancing BLCA research and therapy.